Review of NICE Technology Appraisal Guidance No.34; Trastuzumab for the treatment of advanced breast cancer

Review Decision

The Institute was proposing that it is appropriate for the review to go ahead.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (included in appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and will include the license extension to trastuzumab in combination with docetaxel. The remit for this appraisal will be ‘to appraise the clinical and cost effectiveness of trastuzumab as monotherapy and in combination with a taxane for the treatment of metastatic breast cancer (to include a review of TA34)’.

The review will be scheduled into the work programme at the earliest availability andwe will inform you of the dates in due course.

October 2009